A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib, and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMMA Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib, and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMMTo compare the progression-free survival (PFS) of mezigdomide (CC-92480, also known as BMS-986348), bortezomib and dexamethasone (MeziVd) to that of pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)NCT05519085Matthew Butler, MD

Genetics & Biology of Liver Tumorigenesis in ChildrenGenetics & Biology of Liver Tumorigenesis in ChildrenThe overall goals of this Multi-Investigator Research Proposal is to further the understanding of the development and identify prognostic characteristics of liver tumors in children, particularly hepatoblastoma and its variants through a combined genomic and molecular pathology approach.ClinicalTrials.gov registration not requiredGail Tomlinson MD, PhD

Genetic Epidemiology of Breast and Ovarian CancersGenetic Epidemiology of Breast and Ovarian CancersA research study about factors that might increase the chance of getting breast and ovarian cancers. Eligible: female 18-80 yr old; diagnosed with breast cancer under age 50; diagnosed with ovarian cancer at any age; strong family history of breast and/or ovarian cancer.ClinicalTrials.gov registration not requiredGail Tomlinson MD, PhD

A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of
Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of
Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous This is a Phase 2, randomized, active-controlled, parallel-group, multisite, open-label studyof belzutifan plus fulvestrant versus everolimus plus ETPC (fulvestrant or exemestane) inparticipants with ER+/HER2- unresectable, locally advanced, or mBC.ClinicalTrials.gov registration not requiredSaba Shaikh, MD

MK-5684-015: A Multicenter, Open-label, Phase 2 Basket Study of
MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)MK-5684-015: A Multicenter, Open-label, Phase 2 Basket Study of
MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)MK-5684 is being developed for treatment of solid tumors. This basket study of MK-5684 isdesigned to assess the safety, tolerability, and preliminary efficacy of MK-5684 in selectedadvanced solid tumor indications.ClinicalTrials.gov registration not requiredSaba Shaikh, MD

A Phase 2, Randomized, Multicenter, Open-Label Neoadjuvant Study Evaluating Zanidatamab in Combination with Chemotherapy in Participants with HER2-Positive Breast Cancer A Phase 2, Randomized, Multicenter, Open-Label Neoadjuvant Study Evaluating Zanidatamab in Combination with Chemotherapy in Participants with HER2-Positive Breast Cancer The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer.NCT07102381Saba Shaikh, MD